MedTrace Logo

Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

NCT01196559 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2015-02-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy.

Conditions

Interventions

DRUG

Vinorelbine and Gemcitabine

Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle

Sponsors & Collaborators

  • Korean Cancer Study Group

    collaborator OTHER

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Jae Ho Byun, Professor · Incheon St.Mary;s hospital, Catholic University of Korea

  • Sook Hee Hong, AP · Seoul St.Mary's hospital, Catholic University of Korea

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01196559 on ClinicalTrials.gov